Shots:

• The application is based on P-III KATHERINE study assessing Kadcyla as adjuvant therapy vs Herceptin in ~ 1-500 patients with HER2+ early breast cancer who had invasive residual disease in the breast or axillary lymph nodes following neoadjuvant therapy including Herceptin
• The P-III KATHERINE study results: superiority in invasive disease-free survival as confirmed; no superiority in OS; well tolerated in patients with HER2+ early breast cancer. Chugai plans to expand its HER2 portfolio with the approval of the new indication
• Kadcyla is a combination of Herceptin and CT medicine emtansine and has received FDA’s BT designation- an approved therapy in the US to treat HER2+ m-BC and & early-stage HER2+ BC after surgery- prior treated with Herceptin and Taxane CT

Click here to­ read full press release/ article | Ref: Chugai Pharmaceutical | Image: Twitter